| Toggle SummaryMarch 19, 2020
|
GenMark Receives FDA Emergency Use Authorization for its ePlex® SARS-CoV-2 Test
COVID-19 diagnosis in under two hours now available globally in hospitals on company’s ePlex System Unique sample-to-answer capability enables near patient testing for the most critical patient populations CARLSBAD, Calif. , March 19, 2020 (GLOBE NEWSWIRE) -- GenMark Diagnostics, Inc.
|
View HTML
|
| Toggle SummaryMarch 11, 2020
|
GenMark Diagnostics Announces Submission of Emergency Use Authorization for its ePlex® SARS-CoV-2 Test
CARLSBAD, Calif. , March 11, 2020 (GLOBE NEWSWIRE) -- GenMark Diagnostics, Inc. (NASDAQ:GNMK), a leading provider of automated, multiplex molecular diagnostic testing systems, today announced submission for an Emergency Use Authorization (EUA) to the U.S.
|
View HTML
|
| Toggle SummaryMarch 2, 2020
|
GenMark Diagnostics Reports Fourth Quarter and Full Year 2019 Results
CARLSBAD, Calif. , March 02, 2020 (GLOBE NEWSWIRE) -- GenMark Diagnostics, Inc. (Nasdaq: GNMK), a leading provider of automated, multiplex molecular diagnostic testing systems, today announced financial results for the fourth quarter and year ended December 31, 2019 .
|
View HTML
|
| Toggle SummaryMarch 2, 2020
|
GenMark Diagnostics Announces Global Shipments of ePlex® RUO Test Kits Designed for SARS-CoV-2 Detection
CARLSBAD, Calif. , March 02, 2020 (GLOBE NEWSWIRE) -- GenMark Diagnostics, Inc. (NASDAQ:GNMK), a leading provider of automated, multiplex molecular diagnostic testing systems, today announced the initial shipments of ePlex Research Use Only (RUO) test kits designed to detect the SARS-CoV-2 virus.
|
View HTML
|
| Toggle SummaryFebruary 18, 2020
|
GenMark Diagnostics to Participate in the Cowen Health Care Conference
CARLSBAD, Calif. , Feb. 18, 2020 (GLOBE NEWSWIRE) -- GenMark Diagnostics, Inc. (NASDAQ:GNMK), a leading provider of automated, multiplex molecular diagnostic testing systems, today announced that the company plans to participate in the upcoming Cowen Health Care Conference in Boston, Massachusetts
|
View HTML
|
| Toggle SummaryFebruary 10, 2020
|
GenMark Diagnostics Schedules Fourth Quarter and Full Year 2019 Financial Results Conference Call for March 2, 2020
CARLSBAD, Calif. , Feb. 10, 2020 (GLOBE NEWSWIRE) -- GenMark Diagnostics, Inc. (NASDAQ: GNMK) today announced that it plans to release its fourth quarter and full year earnings results after market close on Monday, March 2, 2020. Management will hold a conference call to review the company's
|
View HTML
|
| Toggle SummaryFebruary 10, 2020
|
GenMark Diagnostics Announces CEO and Chairman Transition
CARLSBAD, Calif. , Feb. 10, 2020 (GLOBE NEWSWIRE) -- GenMark Diagnostics, Inc. (NASDAQ: GNMK), a leading provider of automated, multiplex molecular diagnostic testing systems, today announced that Scott Mendel , Chief Operating Officer, has been appointed Interim President and Chief Executive
|
View HTML
|
| Toggle SummaryJanuary 13, 2020
|
GenMark Diagnostics Provides Preliminary Operational and Financial Results for 2019
CARLSBAD, Calif. , Jan. 13, 2020 (GLOBE NEWSWIRE) -- GenMark Diagnostics, Inc. (NASDAQ: GNMK), a leading provider of automated, multiplex molecular diagnostic testing systems, today provided preliminary operational and financial results for the year ended December 31, 2019 .
|
View HTML
|
| Toggle SummaryDecember 30, 2019
|
GenMark Diagnostics to Participate in the J.P. Morgan Healthcare Conference
CARLSBAD, Calif. , Dec. 30, 2019 (GLOBE NEWSWIRE) -- GenMark Diagnostics, Inc. (NASDAQ:GNMK), a leading provider of automated, multiplex molecular diagnostic testing systems, today announced that the company plans to participate in the upcoming J.P. Morgan Healthcare conference in San Francisco,
|
View HTML
|
| Toggle SummaryNovember 13, 2019
|
GenMark Diagnostics to Participate in Upcoming Investor Conferences
CARLSBAD, Calif. , Nov. 13, 2019 (GLOBE NEWSWIRE) -- GenMark Diagnostics, Inc. (NASDAQ:GNMK), a leading provider of automated, multiplex molecular diagnostic testing systems, today announced that the company plans to participate in two upcoming investor conferences.
|
View HTML
|
